Dual Antiplatelet Therapy: How Long Is Long Enough?
- 57 Downloads
Purpose of review
The optimal duration of dual antiplatelet therapy (DAPT) has been a topic of considerable interest in recent years, as the risk of stent thrombosis has decreased with newer generation stents and the impact of significant bleeding events on clinical outcomes is increasingly apparent. The purpose of this review is to highlight the landmark studies examining short-duration (6 months or less) and extended-duration (greater than 12 months) DAPT as well as provide information about prediction tools to help guide individualized patient treatment decisions.
Short-duration DAPT is acceptably safe when clinically necessary, though recent trials demonstrate non-significant trends towards increased risk of ischemic events with shorter durations. Extended-duration DAPT clearly confers a reduced risk of subsequent ischemic events but at an increased risk of bleeding.
Understanding the perceived ischemic and bleeding risks for each individual patient is paramount in deciding targeted DAPT duration. For patients at a higher bleeding risk with a low ischemic risk, short-duration DAPT (6 months) is acceptable. For patients with continued ischemic risk factors and a low bleeding risk, extended-duration DAPT (up to 30 months) is recommended. The PRECISE DAPT and DAPT prediction tools are helpful in making this determination.
KeywordsDual antiplatelet therapy (DAPT) P2Y12 inhibitors Acute coronary syndrome Coronary artery disease Risk assessment
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68(10):1082–115.CrossRefGoogle Scholar
- 2.Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60.CrossRefGoogle Scholar
- 3.Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–8.CrossRefGoogle Scholar
- 6.Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505–13.CrossRefGoogle Scholar
- 9.Didier R, Morice MC, Barragan P, Noryani AAL, Noor HA, Majwal T, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for DES after discontinuation of clopidogrel). JACC Cardiovasc Interv. 2017;10(12):1202–10.CrossRefGoogle Scholar
- 13.Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274–84.CrossRefGoogle Scholar
- 15.• Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018;363:k3793 This prospective, randomized trial demonstrates that 6 months of DAPT for patients with STEMI and therefore high ischemic risk is non-inferior to the standard 12 months of therapy.CrossRefGoogle Scholar
- 16.American College of Cardiology. TCT17 Presentation Slides | REDUCE 2017, November 1 [Available from: https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=D7E42D5E9C4E4699AF190266BC07E47B.
- 18.US National Library of Medicine Clinical Trials. XIENCE 28 Global Study 2018, December 6, [Available from: https://clinicaltrials.gov/ct2/show/NCT03355742.
- 19.US National Library of Medicine Clinical Trials. A randomized controlled trial with resolute Onyx in one month dual antiplatelet therapy (DAPT) for high-bleeding risk patients (Onyx ONE) 2018, October 11 [Available from: https://clinicaltrials.gov/ct2/show/NCT03344653.
- 20.US National Library of Medicine Clinical Trials. XIENCE 90: a safety evaluation of 3-month DAPT after XIENCE implantation for HBR patients.: US National Library of Medicine Clinical Trials; 2018, December 6. [Available from: https://clinicaltrials.gov/ct2/show/NCT03218787.
- 21.US National Library of Medicine Clinical Trials EVOLVE Short DAPT Study 2018, September 20 [Available from: https://clinicaltrials.gov/ct2/show/NCT02605447.
- 23.US National Library of Medicine Clinical Trials. Randomized trial of COBRA PzF stenting to reduce duration of triple therapy (COBRA-REDUCE). 2018, December 14.Google Scholar
- 32.Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–34.CrossRefGoogle Scholar